Sphingobium yanoikuyae peritonitis in peritoneal dialysis: a case report.

Authors

DOI:

https://doi.org/10.25796/bdd.v6i3.80703

Keywords:

peritoneal dialysis, Sphingobium yanoikuyae, peritonitis, antibotic resistance

Abstract

Full text : click on the pdf icon or https://bdd.rdplf.org/index.php/bdd/article/view/80703/72043

We report a rare clinical case of infection with the bacterium Sphingobium yanoikuyae in an 87-year-old patient undergoing peritoneal dialysis for end-stage renal failure. Sphingobium yanoikuyae is an aerobic, gram-negative bacterium known for its ability to degrade polycyclic aromatic hydrocarbons and its bioremediation potential. A member of the Sphingomonadaceae family, it has been identified in a variety of environments, including dialysis equipment.
After starting peritoneal dialysis, the patient developed an infectious syndrome. Bacteriological analysis of the peritoneal effluent revealed the presence of Sphingobium yanoikuyae in the dialysate. Appropriate antibiotic therapy with MEROPENEM was instituted as soon as the Sphyngobium antibiogram was obtained. A second bacterium, Shingomonas sp, was also identified later (resistant to MEROPENEM). Due to the favorable clinicobiological course, only Sphyngobium was considered responsible for the disease.
This is the first known case of human infection with Sphingobium yanoikuyae, and the third case of infection with a Sphingobium species in a peritoneal dialysis setting. The low prevalence of this germ in human infections suggests a low virulence of this bacterium. Nevertheless, this highlights the potential risk of nosocomial infections linked to this family of bacteria. This germ has shown antibiotic resistance, raising concerns about anti-infective resistance in opportunistic bacteria such as Sphingomonadaceae.
This case adds to our knowledge of rare, antibiotic-resistant infections in the hospital setting, particularly in vulnerable patients treated with peritoneal dialysis.

Introduction

Sphingobium yanoikuyae is a short, rod-shaped, strictly aerobic, gram-negative, non-motile, non-spore-forming bacterium of the Sphingomonadaceae family. It is a hydrophilic bacterium capable of forming biofilms.

Bacteria of the Sphingomonadaceae family have been described in various terrestrial and aquatic environments, including dialysis and water supply equipment (1). Sphingobium yanoikuyae is implicated in the degradation of polycyclic aromatic hydrocarbons. This could be exploited in the development of bioremediation technologies (2).

Peritonitis in peritoneal dialysis is associated with significant morbidity and mortality, and in 4% of cases it can lead to death, damage to the peritoneal membrane, and withdrawal of the dialysis catheter, with temporary or permanent recourse to hemodialysis.

Evolution of the taxonomy of the genera Sphingomonas and Sphingobium

Also belonging to the Sphingomonadaceae family, the Sphingomonas genus was described in 1990 by Yabuuchi et al. (3), identifyingSphingomonas paucimobilisas the type species, and new species in the genus including Sphingomonas yanoikuyae.

The first description of the Sphingobium genus was made by Takeuchi et al. in 2001 (4), distinguishing it from Sphingomonas after phylogenetic analyses of 16S rRNA gene sequences. Sphingobium yanoikuyae is the type species of the genus Sphingobium (5).

Sphingomonas yanoikuyae is the basionym of Sphingobium yanoikuyae, although nomenclature defines them as two distinct species.

While a dozen human Sphingomonas infections of different types have been described (6,7), only two cases of human infections caused by Sphingobium species have been reported. These latter cases involved infection of peritoneal dialysis fluid:

-Sphingobium oleiperitonitis (8)

-Sphingobium lactosutensperitonitis (9)

Clinical observation

We describe here an 87-year-old patient followed in nephrology for end-stage renal failure of diabetic and vascular origin. He has been treated with peritoneal dialysis since the end of May 2023, after catheter placement in mid-April. The patient was trained and then educated in continuous ambulatory peritoneal dialysis (CAPD). After this education phase, the patient was able to carry out his care independently at home. The peritoneal dialysis protocol included two isotonic bags during the day and one Icodextrin bag at night, six days a week.

A few days after initiation of peritoneal dialysis, the patient presented a deterioration in general condition, accompanied by diabetic imbalance, warranting hospitalization due to the intensity of the anorexia. Clinical examination was unremarkable except for constipation for three days.

Initial laboratory workup revealed an infectious syndrome, with C-reactive protein at 223 mg/l, hyperleukocytosis at 10.9 G/L, and slightly increased procalcitonin at 0.67 ng/ml.

On 2023-06-06, analysis of the dialysate showed a cloudy appearance, with a negative blood agar culture on the first bag. Nevertheless, cellular analysis of this first dialysate sample showed an increase in leukocytes to 750/mm3, including 472 neutrophils per mm3, with numerous mesothelial cells and macrophages.

While analysis of the second bag showed no significant increase in leukocytes (48/mm3 including 13% neutrophils, 43% lymphocytes, 25% histiocytic cells), a culture on blood agar identified in 36 hours:

-Numerous Sphingobium yanoikuyae:

– -Sensitive: meropenem, ceftazidime + avibactam

– -Intermediate: ceftazidime, ciprofloxacin

– -Resistant: ceftriaxone, amoxicillin

— -Fairly numerousSphingomonassp.:

– -Sensitive: amoxicillin and ciprofloxacin

– -Resistant: meropenem, ceftazidime, ceftriaxone, ceftazidime + avibactam

These two bacteria are closely related in genus but remain distinct.

On both bags, neither direct examination nor blood cultures on dialysate taken simultaneously identified any germs.

The patient was initially treated with vancomycin 1 gram and ceftriaxone 2 grams IV probabilistic therapy. As soon as theSphingobiumantibiogram was obtained, the patient was switched to meropenem 1 gram/d IV, then intraperitoneally with 6-hour stasis for a total of three weeks. A second bacterium, Sphingomonas sp. (resistant to MEROPENEM), was also identified later. Given the favorable clinico-biological course, only Sphingobium was considered to be responsible for the disease.

During hospitalization, the patient developed a peripheral a frigore facial paralysis, with sudden deafness, which did not regress. No etiology was identified for these symptoms. There was possible neurotoxicity of meropenem (10,11) but no plasma meropenem assays were performed to support this hypothesis. Nevertheless, this prescription was in line with antibiotic therapy recommendations for dialysis patients.

Bacteriological analysis of the dialysate came back sterile after 48 hours of treatment, with an improvement in clinical condition and a favorable evolution of biological inflammatory markers.

Conclusion

This clinical case reports the first case of human infection with Sphingobium yanoikuyae, and it is the third case of Sphingobium infection, all in the context of peritoneal dialysis fluid infection.

This picture of pauci-symptomatic peritonitis, which progressed favorably under antibiotic therapy targeting Sphingobium yanoikuyae and not covering the susceptibility of Sphingomonas sp., is in favor of low virulence in our patient.

However, although rare, descriptions in the literature of infections with Sphingomonas species suggest an increase in the incidence of nosocomial infections with the Sphingomonadaceae family, whose resistance profile is still poorly studied (nevertheless, an intrinsic resistance to colistin and an extended resistance to beta-lactams have been described). Their omnipresence in the environment and their adaptability constitute a natural reservoir of antibiotic resistance, which is potentially dangerous for humans due to their opportunistic nature (12).

Ethical considerations

The patient has given his consent for the publication of this clinical case.

Role des auteurs

Sara Mouradi: patient management, article writing

Gérard Motte: proofreading the article

Stéphane Torner: proofreading the article

Pierre Lebugle: patient management

Nelly Petitboulanger: bacteriological analysis of samples

Aziz Bemmerzouk: final proofreading of the article

Pierre-Yves Charles: bibliography, article writing, proofreading, final corrections

References

  1. Gan H.M., Gan H.Y., Ahmad N.H., Aziz
.....

References

Gan HM, Gan HY, Ahmad NH, Aziz NA, Hudson AO, Savka MA. Whole genome sequencing and analysis reveal insights into the genetic structure, diversity and evolutionary relatedness of luxI and luxR homologs in bacteria belonging to the Sphingomonadaceae family. Front Cell Infect Microbiol. 2014;4:188. DOI: https://doi.org/10.3389/fcimb.2014.00188

Cunliffe M, Kertesz MA. Autecological properties of soil sphingomonads involved in the degradation of polycyclic aromatic hydrocarbons. Appl Microbiol Biotechnol. oct 2006;72(5):1083‑9. DOI: https://doi.org/10.1007/s00253-006-0374-x

Yabuuchi E, Yano I, Oyaizu H, Hashimoto Y, Ezaki T, Yamamoto H. Proposals of Sphingomonas paucimobilis gen. nov. and comb. nov., Sphingomonas parapaucimobilis sp. nov., Sphingomonas yanoikuyae sp. nov., Sphingomonas adhaesiva sp. nov., Sphingomonas capsulata comb. nov., and two genospecies of the genus Sphingomonas. Microbiol Immunol. 1990;34(2):99‑119. DOI: https://doi.org/10.1111/j.1348-0421.1990.tb00996.x

Takeuchi M, Hamana K, Hiraishi A. Proposal of the genus Sphingomonas sensu stricto and three new genera, Sphingobium, Novosphingobium and Sphingopyxis, on the basis of phylogenetic and chemotaxonomic analyses. Int J Syst Evol Microbiol. juill 2001;51(Pt 4):1405‑17. DOI: https://doi.org/10.1099/00207713-51-4-1405

Parte AC, Sardà Carbasse J, Meier-Kolthoff JP, Reimer LC, Göker M. List of Prokaryotic names with Standing in Nomenclature (LPSN) moves to the DSMZ. Int J Syst Evol Microbiol. 2020;70(11):5607‑12. DOI: https://doi.org/10.1099/ijsem.0.004332

Guner Ozenen G, Sahbudak Bal Z, Bilen NM, Yildirim Arslan S, Aydemir S, Kurugol Z, et al. The First Report of Sphingomonas yanoikuyae as a Human Pathogen in a Child With a Central Nervous System Infection. Pediatr Infect Dis J. 1 déc 2021;40(12):e524. DOI: https://doi.org/10.1097/INF.0000000000003301

Lin JN, Lai CH, Chen YH, Lin HL, Huang CK, Chen WF, et al. Sphingomonas paucimobilis bacteremia in humans: 16 case reports and a literature review. J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi. févr 2010;43(1):35‑42. DOI: https://doi.org/10.1016/S1684-1182(10)60005-9

Ruiter NM, Cnossen TT, Bakker RC, van Keulen PJH. Sphingobium olei peritonitis: peritoneal dialysis in turmoil? Perit Dial Int J Int Soc Perit Dial. 2013;33(1):102‑3. DOI: https://doi.org/10.3747/pdi.2012.00080

Palleti SK, Bavi SR, Fitzpatrick M, Wadhwa A. First Case Report of Sphingobium lactosutens as a Human Pathogen Causing Peritoneal Dialysis-Related Peritonitis. Cureus. juill 2022;14(7):e27293. DOI: https://doi.org/10.7759/cureus.27293

Millar Vernetti P, Dalamo K, Khan Z, Gonzalez-Duarte A, Frucht S, Kaufmann H. Meropenem-Induced Facial Myoclonus. Mov Disord Clin Pract. août 2023;10(Suppl 3):S21‑3. DOI: https://doi.org/10.1002/mdc3.13777

Norrby SR. Neurotoxicity of carbapenem antibacterials. Drug Saf. août 1996;15(2):87‑90. DOI: https://doi.org/10.2165/00002018-199615020-00001

Vaz-Moreira I, Nunes OC, Manaia CM. Diversity and antibiotic resistance patterns of Sphingomonadaceae isolates from drinking water. Appl Environ Microbiol. 15 août 2011;77(16):5697‑706. DOI: https://doi.org/10.1128/AEM.00579-11

Submitted

2023-09-25

Published

2023-11-13

How to Cite

1.
Mouradi S, Motte G, Torner S, Lebugle P, Petitboulanger N, Bemmerzouk A, Charles P-Y. Sphingobium yanoikuyae peritonitis in peritoneal dialysis: a case report. Bull Dial Domic [Internet]. 2023 Nov. 13 [cited 2025 Nov. 1];6(3):123-7. Available from: https://bdd.rdplf.org/index.php/bdd/article/view/80703